Fruquintinib vs bevacizumab plus chemo for RAS-mutant colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two treatments for people with a specific type of advanced colorectal cancer that has a RAS mutation. It tests if fruquintinib works as well as the standard combination of bevacizumab and chemotherapy in people who have already had one round of chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have metastatic colorectal cancer that cannot be removed with surgery and has a RAS mutation
- You have already received one prior chemotherapy treatment containing drugs like 5-FU or capecitabine plus oxaliplatin or irinotecan
- You are generally able to care for yourself (ECOG performance status 0 or 1)
- You have not taken any anti-angiogenic small molecule drugs like fruquintinib before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination—fruquintinib (a targeted pill) plus TAS-102 (another chemo pill)—against a standard regimen of bevacizumab (Avastin) plus TAS-102 for people whose advanced colorectal cancer has continued to grow after multiple prior treatments.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
This trial tests whether adding TAS-102 to fruquintinib works better than fruquintinib alone for people with advanced colorectal cancer that has stopped responding to other treatments.
This trial compares two drug combinations for patients whose colorectal cancer has spread and worsened after first treatment. You would receive either FOLFOX or FOLFIRI plus fruquintinib, or the same chemo plus bevacizumab, to see which works better.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.